Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MTERF4_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MTERF4_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MTERF4_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MTERF4_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MTERF4_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007265518 | Oral cavity | OSCC | establishment of protein localization to mitochondrion | 88/7305 | 120/18723 | 2.10e-14 | 1.19e-12 | 88 |
GO:01400533 | Oral cavity | OSCC | mitochondrial gene expression | 78/7305 | 108/18723 | 2.37e-12 | 9.86e-11 | 78 |
GO:000662618 | Oral cavity | OSCC | protein targeting to mitochondrion | 72/7305 | 100/18723 | 2.10e-11 | 7.18e-10 | 72 |
GO:004225520 | Oral cavity | OSCC | ribosome assembly | 49/7305 | 61/18723 | 4.73e-11 | 1.50e-09 | 49 |
GO:00009591 | Oral cavity | OSCC | mitochondrial RNA metabolic process | 29/7305 | 49/18723 | 3.33e-03 | 1.42e-02 | 29 |
GO:0022613110 | Oral cavity | LP | ribonucleoprotein complex biogenesis | 259/4623 | 463/18723 | 7.20e-48 | 2.25e-44 | 259 |
GO:0042254110 | Oral cavity | LP | ribosome biogenesis | 173/4623 | 299/18723 | 8.97e-35 | 1.41e-31 | 173 |
GO:000636418 | Oral cavity | LP | rRNA processing | 134/4623 | 225/18723 | 6.08e-29 | 4.23e-26 | 134 |
GO:001607218 | Oral cavity | LP | rRNA metabolic process | 136/4623 | 236/18723 | 2.37e-27 | 1.48e-24 | 136 |
GO:007259419 | Oral cavity | LP | establishment of protein localization to organelle | 205/4623 | 422/18723 | 6.76e-27 | 3.85e-24 | 205 |
GO:0006605110 | Oral cavity | LP | protein targeting | 156/4623 | 314/18723 | 5.43e-22 | 1.62e-19 | 156 |
GO:003447014 | Oral cavity | LP | ncRNA processing | 184/4623 | 395/18723 | 1.20e-21 | 3.12e-19 | 184 |
GO:003466011 | Oral cavity | LP | ncRNA metabolic process | 205/4623 | 485/18723 | 6.46e-18 | 1.09e-15 | 205 |
GO:0042255110 | Oral cavity | LP | ribosome assembly | 44/4623 | 61/18723 | 8.20e-15 | 1.05e-12 | 44 |
GO:000683919 | Oral cavity | LP | mitochondrial transport | 119/4623 | 254/18723 | 1.06e-14 | 1.33e-12 | 119 |
GO:007058519 | Oral cavity | LP | protein localization to mitochondrion | 70/4623 | 125/18723 | 6.73e-14 | 7.02e-12 | 70 |
GO:007265519 | Oral cavity | LP | establishment of protein localization to mitochondrion | 68/4623 | 120/18723 | 6.98e-14 | 7.16e-12 | 68 |
GO:000662619 | Oral cavity | LP | protein targeting to mitochondrion | 58/4623 | 100/18723 | 1.23e-12 | 1.00e-10 | 58 |
GO:014005312 | Oral cavity | LP | mitochondrial gene expression | 53/4623 | 108/18723 | 3.54e-08 | 1.27e-06 | 53 |
GO:007259417 | Prostate | Tumor | establishment of protein localization to organelle | 151/3246 | 422/18723 | 3.19e-20 | 2.83e-17 | 151 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MTERF4 | SNV | Missense_Mutation | rs770916374 | c.16N>T | p.Arg6Cys | p.R6C | Q7Z6M4 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-A2-A0ER-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
MTERF4 | SNV | Missense_Mutation | novel | c.683N>A | p.Gly228Asp | p.G228D | Q7Z6M4 | protein_coding | tolerated(0.62) | benign(0.011) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
MTERF4 | SNV | Missense_Mutation | | c.344N>G | p.Val115Gly | p.V115G | Q7Z6M4 | protein_coding | tolerated(0.13) | benign(0.16) | TCGA-B6-A1KN-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MTERF4 | insertion | Frame_Shift_Ins | novel | c.562_563insGGAATCACTATGTATTTCCTTCT | p.Thr188ArgfsTer70 | p.T188Rfs*70 | Q7Z6M4 | protein_coding | | | TCGA-BH-A0BV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
MTERF4 | SNV | Missense_Mutation | novel | c.757T>C | p.Tyr253His | p.Y253H | Q7Z6M4 | protein_coding | deleterious(0) | possibly_damaging(0.766) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
MTERF4 | SNV | Missense_Mutation | | c.438G>T | p.Lys146Asn | p.K146N | Q7Z6M4 | protein_coding | deleterious(0.04) | benign(0.42) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
MTERF4 | SNV | Missense_Mutation | novel | c.633N>C | p.Gln211His | p.Q211H | Q7Z6M4 | protein_coding | deleterious(0.03) | benign(0.329) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MTERF4 | SNV | Missense_Mutation | rs377505682 | c.386C>T | p.Ser129Leu | p.S129L | Q7Z6M4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MTERF4 | SNV | Missense_Mutation | rs763068285 | c.104C>T | p.Thr35Met | p.T35M | Q7Z6M4 | protein_coding | tolerated_low_confidence(0.28) | benign(0.003) | TCGA-B5-A0JZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
MTERF4 | SNV | Missense_Mutation | | c.586N>A | p.Asp196Asn | p.D196N | Q7Z6M4 | protein_coding | tolerated(0.55) | benign(0.005) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |